Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., located in the North San Diego County city of Carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. We are the pioneer in the discovery and development of antisense drugs with more than 1300 patents.
Ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. Our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. We are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. Join us and experience our unique culture while you develop and expand your career.
736 articles with Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed IONIS-AZ5-2.5 Rx (AZD2373) to the global, science-led biopharmaceutical company AstraZeneca (NYSE: AZN).
The New England Journal of Medicine Publishes Biogen's SPINRAZA (nusinersen) Phase III Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
Data from the other endpoints analyzed, including attainment of new motor milestones and upper limb motor function, were consistently in favor of individuals who received treatment and were considered clinically significant.
A webcast replay will be available for a limited time at the same address.
The FDA has set a PDUFA date of July 6, 2018.
Ionis Pharma Announces the Initiation of a Clinical Study of its First Orally Delivered Antisense Drug for the Treatment of Gastrointestinal Disorders
Ionis Pharma today announced that it has earned a $5M milestone payment associated with initiation and enrollment in a newly initiated Phase 1 clinical study.
Biogen will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization.
The two companies will work together to transition the ongoing open-label extension study to Roche, which will be responsible for managing this study and all future studies.
12/12/2017Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its "Throttle" technology.
The success has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of $45 million.
Ionis Pharma Licenses IONIS-HTT Rx to Partner Following Successful Phase I/II Study in Patients With Huntington's Disease
Roche will now be responsible for all development and commercial activities.
Ionis Pharma and Janssen have strengthened their alliance with a second deal for gastrointestinal drugs.
Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS
FDA Prescription Drug User Fee Act goal date set for August 30, 2018.
AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3, or ANGPTL3.
11/9/2017Ionis earns $5 million license fee from Dynacure.
The Company ended the third quarter with over $1B in cash.
In Monia's new role, he will be responsible for transitioning research programs into development.
Inotersen is an antisense drug designed to reduce the production of transthyretin, or TTR, to treat patients with TTR amyloidosis, a severe, rare and fatal disease.
11/3/2017The MAA will be reviewed under the EMA's Accelerated Assessment program.
Alnylam and Sanofi Genzyme presented positive Phase III results of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy at a conference in France.
The NEURO-TTR study met both co-primary endpoints, the Norfolk QoL-DN, a validated instrument for physician-assessed quality of life, and mNIS+7, a validated instrument for evaluating hATTR disease severity.